Overview

Lenalidomide in the Treatment of Refractory Cutaneous Dermatomyositis

Status:
Not yet recruiting
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
The goal of this study is to evaluate the efficacy and safety of lenalidomide in the treatment of patients with active cutaneous DM.
Phase:
N/A
Details
Lead Sponsor:
Jiangxi Provincial People's Hopital
Treatments:
Lenalidomide